Gaps in the Assessment and Care of Neurodevelopmental and Psychiatric Conditions Associated With Dystrophinopathy
Muscle & Nerve · 2025
DOI: 10.1002/mus.28316 ↗Kurz gefasst
Fachartikel in der Zeitschrift Muscle & Nerve, 2025. Verfasst von Olivia Baldi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne, Neurodevelopmental Disorders, Mental Disorders. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Parent Project Muscular Dystrophy.
Abstract (Originalsprache)
Introduction/Aims While dystrophinopathies are primarily characterized by progressive muscle weakness with onset during childhood, dystrophin also plays a role in brain development. This study aimed to characterize how neurodevelopmental and psychiatric disorders are currently identified and managed in clinical care of those with Becker and Duchenne muscular dystrophy (BDMD).
Methods
Parent Project Muscular Dystrophy (PPMD) disseminated surveys to caregivers and health care providers (HCPs) in the United States to assess the frequency and management of neurodevelopmental and psychiatric disorders of those with dystrophinopathy.
Results
320 caregivers (C) and 74 HCPs responded to surveys. Caregivers indicated higher rates of neurodevelopmental and psychiatric disorders than HCPs, including anxiety (50.5% C, n = 112; 17.8% HCP, n = 19), attention‐deficit hyperactivity disorder (ADHD) (32.0% C, n = 73; 15.9% HCP, n = 17), obsessive‐compulsive disorder (OCD) (25.9% C, n = 57; 11.2% HCP, n = 12), depression (21.6% C, n = 48; 18.7% HCP, n = 20), and autism spectrum disorder (ASD) (21.0% C, n = 47; 10.3% HCP, n = 11). Results also indicated gaps in the assessment and care of these conditions, including lack of routine screening, reduced access to psychologists and psychiatrists, and lack of clarity amongst HCPs about who should manage neurodevelopmental and psychiatric concerns in those with dystrophinopathy.
Discussion
Closing the identified gaps in assessment, perception, and care will require increased awareness of neurodevelopmental and psychiatric conditions in dystrophinopathy and screening tools to facilitate early identification of these conditions during routine clinical care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Harvard Graduate School of Education, Cambridge, Massachusetts, USA.
- Parent Project Muscular Dystrophy, Washington, DC, USA.
- Departments of Psychology and Neurology, Nationwide Children's Hospital, Columbus, Ohio, USA.
- Department of Pediatrics, The Ohio State University, Columbus, Ohio, USA.
- Department of Pediatrics, University of Arkansas for Medical Sciences, Arkansas Children's Hospital, Little Rock, Arkansas, USA.
ORCID-Profile: Aravindhan Veerapandiyan, Mary K Colvin
Förderung
- Parent Project Muscular Dystrophy
Zitieren
APA
Baldi, O., Kinnett, K., Schrader, R., Denger, B., Truba, N., Sorensen, S., Veerapandiyan, A., & Colvin, M. K. (2025). Gaps in the Assessment and Care of Neurodevelopmental and Psychiatric Conditions Associated With Dystrophinopathy. Muscle & Nerve. https://doi.org/10.1002/mus.28316
Vancouver
Baldi O, Kinnett K, Schrader R, Denger B, Truba N, Sorensen S, et al. Gaps in the Assessment and Care of Neurodevelopmental and Psychiatric Conditions Associated With Dystrophinopathy. Muscle & Nerve. 2025. doi:10.1002/mus.28316
BibTeX
@article{Baldi2025,
author = {Baldi, Olivia and Kinnett, Kathi and Schrader, Rachel and Denger, Brian and Truba, Natalie and Sorensen, Seth and Veerapandiyan, Aravindhan and Colvin, Mary K},
title = {Gaps in the Assessment and Care of Neurodevelopmental and Psychiatric Conditions Associated With Dystrophinopathy},
journal = {Muscle & Nerve},
year = {2025},
doi = {10.1002/mus.28316}
}
EUVIMED